130 related articles for article (PubMed ID: 38030195)
1. Ramucirumab Plus Paclitaxel as a Second-line Chemotherapy in Older Adults With Advanced Gastric Cancer (YCOG1601).
Sato S; Kunisaki C; Tamura Y; Yago A; Kasahara K; Sato T; Kondo H; Kosaka T; Akiyama H; Endo I
Anticancer Res; 2023 Dec; 43(12):5663-5670. PubMed ID: 38030195
[TBL] [Abstract][Full Text] [Related]
2. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
[TBL] [Abstract][Full Text] [Related]
4. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
5. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
[TBL] [Abstract][Full Text] [Related]
7. Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).
Lorenzen S; Schwarz A; Pauligk C; Goekkurt E; Stocker G; Knorrenschild JR; Illerhaus G; Dechow T; Moehler M; Moulin JC; Pink D; Stahl M; Schaaf M; Goetze TO; Al-Batran SE
BMC Cancer; 2023 Jun; 23(1):561. PubMed ID: 37337155
[TBL] [Abstract][Full Text] [Related]
8. SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer.
Boisteau E; François E; Aparicio T; Le Malicot K; Boulahssass R; Lecomte T; Laurent-Puig P; Guiu B; Paillaud E; Galais MP; Lopez-Trabada Ataz D; Tougeron D; Dourthe LM; Guimbaud R; Samalin E; Moreau M; Louvet C; Lepage C; Lièvre A
Dig Liver Dis; 2022 Jun; 54(6):747-754. PubMed ID: 35351371
[TBL] [Abstract][Full Text] [Related]
9. Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study.
Nara K; Yamamoto T; Yamashita H; Yagi K; Takada T; Seto Y; Suzuki H
BMC Cancer; 2023 Oct; 23(1):979. PubMed ID: 37833660
[TBL] [Abstract][Full Text] [Related]
10. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
11. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.
Lorenzen S; Thuss-Patience P; Pauligk C; Gökkurt E; Ettrich T; Lordick F; Stahl M; Reichardt P; Sökler M; Pink D; Probst S; Hinke A; Goetze TO; Al-Batran SE
Eur J Cancer; 2022 Apr; 165():48-57. PubMed ID: 35202974
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
Di Bartolomeo M; Niger M; Morano F; Corallo S; Antista M; Tamberi S; Lonardi S; Di Donato S; Berardi R; Scartozzi M; Cardellino GG; Di Costanzo F; Rimassa L; Luporini AG; Longarini R; Zaniboni A; Bertolini A; Tomasello G; Pinotti G; Scagliotti G; Tortora G; Bonetti A; Spallanzani A; Frassineti GL; Tassinari D; Giuliani F; Cinieri S; Maiello E; Verusio C; Bracarda S; Catalano V; Basso M; Ciuffreda L; De Vita F; Parra HS; Fornaro L; Caporale M; de Braud F; Pietrantonio F
BMC Cancer; 2019 Mar; 19(1):283. PubMed ID: 30922323
[TBL] [Abstract][Full Text] [Related]
13. Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer.
Muro K; Oh SC; Shimada Y; Lee KW; Yen CJ; Chao Y; Cho JY; Cheng R; Carlesi R; Chandrawansa K; Orlando M; Ohtsu A
J Gastroenterol Hepatol; 2016 Mar; 31(3):581-9. PubMed ID: 26317322
[TBL] [Abstract][Full Text] [Related]
14. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
Shitara K; Muro K; Shimada Y; Hironaka S; Sugimoto N; Komatsu Y; Nishina T; Yamaguchi K; Segawa Y; Omuro Y; Tamura T; Doi T; Yukisawa S; Yasui H; Nagashima F; Gotoh M; Esaki T; Emig M; Chandrawansa K; Liepa AM; Wilke H; Ichimiya Y; Ohtsu A
Gastric Cancer; 2016 Jul; 19(3):927-38. PubMed ID: 26510663
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
Nakasya A; Hagiwara Y; Ikoma T; Kurioka Y; Matsumoto T; Yamamoto Y; Tsuduki T; Kajiwara T; Moriwaki T; Nishina T; Yamashita N; Hyodo I
Int J Clin Oncol; 2022 Apr; 27(4):684-694. PubMed ID: 35089459
[TBL] [Abstract][Full Text] [Related]
16. Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303).
Kobayashi D; Mochizuki Y; Torii K; Takeda S; Kawase Y; Ishigure K; Teramoto H; Ando M; Kodera Y
Int J Clin Oncol; 2020 Oct; 25(10):1793-1799. PubMed ID: 32567012
[TBL] [Abstract][Full Text] [Related]
17. Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma.
Moy RH; Greally M; Chou JF; Li J; Desai AM; Chalasani SB; Won E; Kelsen DP; Ilson DH; Janjigian YY; Capanu M; Ku GY
Cancer Chemother Pharmacol; 2022 Feb; 89(2):255-265. PubMed ID: 35066693
[TBL] [Abstract][Full Text] [Related]
18. Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
Kim BJ; Jee HJ; Rha SY; Han HS; Ryu MH; Park SH; Kim JG; Bae WK; Lee KW; Oh DY; Byun JH; Kim DS; Suh YJ; An H; Zang DY
Gastric Cancer; 2022 May; 25(3):609-618. PubMed ID: 35015188
[TBL] [Abstract][Full Text] [Related]
19. Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.
Nakanishi K; Tanaka C; Kanda M; Miyata K; Machida N; Sakai M; Kobayashi D; Teramoto H; Ishiyama A; Sato B; Oshima T; Kajikawa M; Matsushita H; Ishigure K; Yamashita K; Fujitake S; Sueoka S; Asada T; Shimizu D; Sugita S; Kuwatsuka Y; Maeda O; Furune S; Murotani K; Ando Y; Ebata T; Kodera Y
Nagoya J Med Sci; 2024 Feb; 86(1):43-51. PubMed ID: 38505718
[TBL] [Abstract][Full Text] [Related]
20. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
